The paperwork, sometimes called the medication guide or patient package insert, may contain details about interactions. If Eylea doesn’t come with paperwork, you can ask your pharmacist to print ...

Australian biotech Opthea (Nasdaq: OPT) is cutting around two-thirds of its workforce, as the company moves to curb spending ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.

had infringed on U.S. Patent 11,084,865, claimed to cover a vial containing Eylea. As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%.

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung Huynh tells investors in “negative, but ...

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader. The TALON trial ...

Historically, the most common treatment for wet macular degeneration (wAMD) involved anti-vascular endothelial growth factor (VEGF) injections, such as Avastin, Lucentis, and Eylea. These drugs work ...

Nearly four in 10 shoppers have had a package stolen. This is according to a study commissioned by ValuePenguin. Although the number of deliveries increases during the holidays, package theft is ...

Are side effects of Vabysmo similar to those seen with Eylea? Yes, Vabysmo (faricimab-svoa) can cause side effects that are similar to those of Eylea (aflibercept). Both medications are eye ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently established that Amgen’s biosimilar Pavblu violates key patents of Eylea. A U.S.